title: Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival.
abstract: Allelic imbalance or loss of heterozygosity (LOH) studies have been used extensively to identify regions on chromosomes that may contain putative tumour-suppressor genes. We have undertaken an extensive allelotype of 80 specimens of squamous cell carcinoma of the head and neck (SCCHN) using 145 polymorphic microsatellite markers on 39 chromosome arms. Allelic imbalances were found most frequently on chromosome arms 3p, 9p, 17p and 18q with over 45% LOH and imbalances on 1p, 1q, 2p, 5q, 6p, 6q, 8p, 8q, 9q, 11q, 13q, 17q and 19q were found in more than 20% of SCCHN. These LOH data were analysed against a range of clinicopathological parameters which included previously untreated and previously treated tumours; correlations were found between LOH on 9q and nodes at pathology (P = 0.02) and between histopathological grade and LOH on 12q (P = 0.02) and 13q (P = 0.01). In the group of previously untreated tumours, a correlation was found between site of tumour and LOH on 3p (P = 0.019), and 8p (P = 0.029), while TNM staging correlated with LOH on 3p (P = 0.019) and 17p (P = 0.016). Fractional allele loss (FAL) was calculated for 52 tumours with LOH data on nine or more chromosomal arms and found to have a median value of 0.22 (range 0.0-0.80). Correlations were found between FAL > median value and nodes at pathology (P = 0.01) and tumour grade (P = 0.06), demonstrating that advanced tumours with lymph node metastasis often had LOH at multiple sites. FAL > median value was found to correlate with a poor survival (P < 0.03) and, furthermore, FAL > median value correlated with poor survival in the previously untreated patients (P < 0.019). These results indicate that assessment of the accumulation of genetic damage, as provided by allelotype data, provides a useful molecular indicator of the tumour behaviour and clinical outcome.
authors.affiliation: Department of Clinical Dental Sciences, University of Liverpool, UK.
authors.forename: J K
authors.initials: JK
authors.lastname: Field
authors.forename: H
authors.initials: H
authors.lastname: Kiaris
authors.forename: J M
authors.initials: JM
authors.lastname: Risk
authors.forename: C
authors.initials: C
authors.lastname: Tsiriyotis
authors.forename: R
authors.initials: R
authors.lastname: Adamson
authors.forename: V
authors.initials: V
authors.lastname: Zoumpourlis
authors.forename: H
authors.initials: H
authors.lastname: Rowley
authors.forename: K
authors.initials: K
authors.lastname: Taylor
authors.forename: J
authors.initials: J
authors.lastname: Whittaker
authors.forename: P
authors.initials: P
authors.lastname: Howard
mesh_terms: D000483:Alleles; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D002877:Chromosomes, Human; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D017353:Gene Deletion; D005819:Genetic Markers; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D018895:Microsatellite Repeats; D009367:Neoplasm Staging; D012907:Smoking; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm; D005819:Genetic Markers